Illustration showing deep vein thrombosis. Credit: Blausen / Blausen Medical 2014.

Medtronic has started an investigational device exemption (IDE) study to assess its Abre venous self-expanding stent system in patients suffering from deep venous disease.

Abre is an investigational device being developed for permanent implant in the iliofemoral vein. The device includes a nitinol stent with a tri-axial shaft design, and uses optimised strength and flexibility to exert an outward force for opening the obstructed vein.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

To ensure flexibility and conformability, the stent features an open-cell design with three connection points between the cells.

The multi-centre, single-arm ABRE IDE Study will investigate the safety and effectiveness of the stent in 200 patients with iliofemoral venous outflow obstruction at up to 35 clinical sites in the US and Europe.

ABRE IDE Study European principal investigator Stephen Black said: “Deep venous disease can cause pain, swelling, and blood clots, which can potentially be devastating to patients.

“As a result, there is a critical need for treatment options that are safe, effective, and durable.

“We look forward to using the Abre stent in the restoration of patency in patients with deep venous disease.”

“We look forward to using the Abre stent in the restoration of patency in patients with deep venous disease.”

The primary efficacy endpoint of the study is patency at 12 months defined as freedom from occlusion and clinically driven target lesion revascularisation (CD-TLR).

The study will also monitor the incidence of composite major adverse events (MAE) at 30 days after stenting an obstruction in the iliofemoral vein as the primary safety endpoint.

Medtronic expects that the findings from this study will support its US pre-market approval (PMA) application of the Abre stent to treat symptomatic iliofemoral venous outflow obstruction in venous occlusive disease.